Andrew Walding

136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

Myung‐Ju Ahn, James Chih‐Hsin Yang, Helena A. Yu et al. · Journal of Thoracic Oncology · 2016 · 232 citations · Full text

Tumor Biology, Medicine, Pathology +8

Neoadjuvant Osimertinib With/Without Chemotherapy Versus Chemotherapy Alone for <i>EGFR</i> -Mutated Resectable Non-Small-Cell Lung Cancer: NeoADAURA

Masahiro Tsuboi, Walter Weder, Carles Escriu et al. · Future Oncology · 2021 · 182 citations · Full text

Human peripheral blood mononuclear cells express GABAA receptor subunits

Sabina Alam, David L. Laughton, Andrew Walding et al. · Molecular Immunology · 2005 · 157 citations

G Protein-coupled Receptor, Immunology, Blood Cell +5

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Ying Cheng, Yong He, Wěi Li et al. · Targeted Oncology · 2021 · 156 citations · Full text

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

Yuichiro Ohe, Fumio Imamura, Naoyuki Nogami et al. · Japanese Journal of Clinical Oncology · 2018 · 146 citations · Full text